BioPontis, Taconic partner for preclinical research
BioPontis Alliance and Taconic have entered into a scientific development partnership which will employ Taconic's translational genetically modified models and scientific services in preclinical research efforts to accelerate the advancement of new medical discoveries.

Taconic will serve as BioPontis Alliance's exclusive provider of genetically modified models used in oncology applications, according to the Hudson, New York-based Taconic, which is also the BioPontis' preferred provider for in vivo clinical studies in the areas of oncology, neurology and infectious disease; compound profiling services; phenotyping services; and custom-generated models for use in preclinical efficacy and safety testing.

To support its oncology initiatives, Raleigh, N.C.-based BioPontis also will leverage Taconic's advanced bioluminescent imaging of tumor cells, along with its genetically modified models predisposed to tumor development.